Results 131 to 140 of about 109,033 (289)

Annual 12‐Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Natalizumab (NTZ) is a highly effective therapy for multiple sclerosis (MS); however, its use is limited by the risk of a rare potentially severe opportunistic brain infection, progressive multifocal leukoencephalopathy (PML). Alternative dosing strategies are evaluated to reduce PML risk while still maintaining efficacy, which ...
Regina Berkovich, Tilman Schneider‐Hohendorf, Eric Baetscher, Evan L. Riddle, Marie Deffner, Emily Katsnelson, Janine Ferrant‐Orgettas, Julie Czerkowicz, John Anderson, Susan E. Goelz, Nicholas Schwab   +10 more
wiley   +1 more source

Destination therapy with a rotary blood pump and novel power delivery☆ [PDF]

, 2009
Stephen Westaby, Michael Siegenthaler, Friedhelm Beyersdorf, Massimo Massetti, John Pepper, André Salim Khayat, Roland Hetzer, O.H. Frazier   +7 more
openalex   +1 more source

Exosome Proteomics of SOD1D90A Mutation Suggest Early Disease Mechanisms, and FN1 as a Biomarker

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease. Super oxide dismutase 1 (SOD1) gene mutations cause ALS, and the D90A mutation is associated with primarily upper motor neuron (UMN) loss. Objective Our goal is to reveal the early cellular events in ALS pathology and identify potential pharmacokinetic biomarkers, using well ...
Mukesh Gautam, Ali Laith, Aslihan Gunel, Melda Yilmaz, Nazli Basak, Halil Idrisoglu, P. Hande Ozdinler   +6 more
wiley   +1 more source

Intermittent inotropic support with levosimendan in advanced heart failure as destination therapy: The LEVO-D registry. [PDF]

ESC Heart Fail, 2023
Dobarro D, Donoso-Trenado V, Solé-González E, Moliner-Abós C, Garcia-Pinilla JM, Lopez-Fernandez S, Ruiz-Bustillo S, Diez-Lopez C, Castrodeza J, Méndez-Fernández AB, Vaqueriza-Cubillo D, Cobo-Marcos M, Tobar J, Sagasti-Aboitiz I, Rodriguez M, Escolar V, Abecia A, Codina P, Gómez-Otero I, Pastor F, Marzoa-Rivas R, González-Babarro E, de Juan-Baguda J, Melendo-Viu M, de Frutos F, Gonzalez-Costello J.   +25 more
europepmc   +1 more source

CSF Levels of NPTX2 Are Associated With Less Brain Atrophy Over Time in Cognitively Unimpaired Individuals

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Neuronal pentraxin 2 (NPTX2) is a synaptic protein involved in synaptic plasticity and regulation of neuronal excitability. Lower baseline cerebrospinal fluid (CSF) NPTX2 levels have been shown to be associated with an earlier onset of mild cognitive impairment (MCI), a pre‐dementia syndrome, even after CSF Alzheimer's Disease (AD)
Juan P. Vazquez, Corinne Pettigrew, Yuxin Zhu, Claire Anderson, Guray Erus, Christos Davatzikos, Michael Miller, Abhay Moghekar, Sungtaek Oh, Chan‐Hyun Na, Marilyn Albert, Paul Worley, Anja Soldan   +12 more
wiley   +1 more source

Girls' career aspirations [PDF]

, 2011
"This report evaluates the extent to which careers education, guidance and other provision raise aspirations and inform the choices of courses and careers by girls and young women to support their long-term achievement.

core  

IMPACT OF LEFT VENTRICULAR ASSIST DEVICE DESTINATION THERAPY ON VENTRICULAR RE-SYNCHRONIZATION [PDF]

, 2005
Smitha G. Agadi, Helen Lonergan-Thomas, Sharon L. Brennan‐Olsen, Pamela Cianci, Mark S. Slaughter, Marc A. Silver   +5 more
openalex   +1 more source

Plasma Proteomic Signatures for Alzheimer's Disease: Comparable Accuracy to ATN Biomarkers and Cross‐Platform Validation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background There is growing recognition of the potential of plasma proteomics for Alzheimer's Disease (AD) risk assessment and disease characterization. However, differences between proteomics platforms introduce uncertainties regarding cross‐platform applicability.
Manyue Hu, Oliver Robinson, Christina M. Lill, Anna Matton, Raquel Puerta, Pilar Sanz, Merce Boada, Agustín Ruiz, Lefkos Middleton, for the Alzheimer's Disease Neuroimaging Initiative   +9 more
wiley   +1 more source

Implantable ventricular assistance systems (VAD) as a bridge to transplant or as 'destination therapy'. [PDF]

Eur Heart J Suppl, 2021
Nesta M, Cammertoni F, Bruno P, Massetti M.   +3 more
europepmc   +1 more source

Long‐Term Destination Therapy With the HeartMate XVE Left Ventricular Assist Device: Improved Outcomes Since the REMATCH Study [PDF]

, 2005
James W. Long, Abdallah G. Kfoury, Mark S. Slaughter, Marc A. Silver, Carmelo A. Milano, Joseph G. Rogers, Reynolds M. Delgado, O.H. Frazier   +7 more
openalex   +1 more source